Vimarsana
Biggest News Aggregation in the World

Page 4 - Phasei Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phasei Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phasei Study Today - Breaking & Trending Today

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022 - Vimarsana News

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

Published: June 2, 2022

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
United StatesLin ShenLos AngelesMichael ShiJifang GongClinical Development CentersTranscenta HoldingUniversity Cancer HospitalProduct Development CenterTranslational Research CenterGroup HeadquartersResearch InstituteTranscenta Holding LimitedTranscenta Immune Tolerance Breaking TechnologyPhasei StudyHigh Affinity Humanized Anti ClaudinFirst Line TreatmentProfessor Jifang GongPeking University Cancer HospitalProfessor Lin ShenBeijing CancerImmune Tolerance Breaking TechnologyOrphan Drug DesignationManufacturing FacilityExternal Partnering Center
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting - Vimarsana News

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

Published: April 29, 2022

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
Mccormick PlaceUnited StatesLos AngelesJifang GongTianshu LiuClinical Development CentersTranscenta HoldingAmerican Society Of Clinical OncologyUniversity Cancer HospitalProduct Development CenterTranslational Research CenterGroup HeadquartersPrnewswire Transcenta Holding LimitedFudan UniversityResearch InstituteTranscenta Immune Tolerance Breaking TechnologyBusiness DevelopmentHolding LimitedAmerican SocietyClinical OncologyPhasei StudyHigh Affinity HumanizedFirst Line TreatmentChinese Solid TumorProfessor Jifang Gong
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting - Vimarsana News

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

Published: April 29, 2022

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
Mccormick PlaceUnited StatesLos AngelesJifang GongTianshu LiuClinical Development CentersTranscenta HoldingAmerican Society Of Clinical OncologyUniversity Cancer HospitalProduct Development CenterTranslational Research CenterGroup HeadquartersPrnewswire Transcenta Holding LimitedFudan UniversityResearch InstituteTranscenta Immune Tolerance Breaking TechnologyBusiness DevelopmentHolding LimitedAmerican SocietyClinical OncologyPhasei StudyHigh Affinity HumanizedFirst Line TreatmentChinese Solid TumorProfessor Jifang Gong
Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC - Vimarsana News

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

Published: January 12, 2022

SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ('Transcenta') (HKEX: 06628), a clinical stage biopharmaceutical company w...

Source: businessinsider.com
Related Topics:
Yu ShenUnited StatesMiao ZhangJian ZhangSan FranciscoLin ShenChangsong QiNashaty GabrailChuan QiJianming WangZhenzhong XiaLi XuXueming QianLos AngelesMichael ShiJifang GongWeijian GuoClinical Development CentersTranscenta HoldingInternational Gastric Cancer CongressDrug AdministrationProduct Development CenterTranslational Research CenterGroup HeadquartersTranscenta Holding Limited
Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC - Vimarsana News

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

Published: January 12, 2022

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Source: prnewswire.com
Related Topics:
Yu ShenUnited StatesMiao ZhangJian ZhangSan FranciscoLin ShenChangsong QiNashaty GabrailChuan QiJianming WangZhenzhong XiaLi XuXueming QianLos AngelesMichael ShiJifang GongWeijian GuoClinical Development CentersTranscenta HoldingInternational Gastric Cancer CongressDrug AdministrationProduct Development CenterTranslational Research CenterGroup HeadquartersTranscenta Holding Limited